HER2 Support Group Forums - View Single Post - Genentech Provides Update From Avastin FDA Advisory Committee Meeting

News · 07-22-2010, 04:13 AM

Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one that use of Avastin® (bevacizumab) in combination with paclitaxel for previously untreated (first-line) advanced HER2-negative breast cancer be removed from Avastin's U.S. label...

More...

07-22-2010, 04:13 AM	#1
News Senior Member Join Date: Oct 2007 Posts: 19,870	Genentech Provides Update From Avastin FDA Advisory Committee Meeting Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one that use of Avastin® (bevacizumab) in combination with paclitaxel for previously untreated (first-line) advanced HER2-negative breast cancer be removed from Avastin's U.S. label... More...